Key transaction details
On February 19, 2026, Krystal Biotech, Inc. (NASDAQ: KRYS) director Dino A. Rossi carried out two sales of common stock totaling 18,950 shares. Those dispositions were completed in two separate trades at prices ranging from $260.4858 to $262.1 per share, producing gross proceeds of $4.95 million.
Concurrent option exercise
Also on February 19, Rossi exercised options to acquire 18,950 shares of Krystal Biotech common stock at an exercise price of $8.79 per share. The exercise had a stated total value of $166,570.
Post-transaction holdings and market context
After these transactions, Rossi is recorded as directly owning 78,691 shares of Krystal Biotech common stock. The company's share price has appreciated sharply over the past six months, up approximately 82%, and was trading at $274.33 at the time the transactions were noted.
Recent corporate financials
Krystal Biotech reported fourth-quarter 2025 results that outpaced expectations. The company posted earnings per share of $1.70, ahead of the $1.58 consensus estimate. Revenue for the quarter came in at $107.1 million, topping the forecast of $106.16 million.
The earnings and revenue beats have attracted attention from market participants and analysts, although reports note that specific analyst upgrades or downgrades were not disclosed.
Valuation note
Analysis referenced from InvestingPro indicates that Krystal Biotech's stock remains undervalued relative to its Fair Value. That analysis is available through the company’s Pro Research Report, which is published alongside 14 additional ProTips.
Summation
The combination of a director sale, a concurrent option exercise, strong quarterly financial performance and a significant six-month share-price gain provides multiple data points for market observers. The record shows precise transaction prices, option exercise details and updated ownership figures without indicating any changes in analyst ratings.